All In MedTech

FDA Clearance Tracker · P140003-S074

Impella 2.5 System, Impella CP System and Impella CP System with SmartAssist System, Impella 5.0 System, Impella LD Syst

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 10, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 10, 2021

Approved

Time to decision

252 days

Received Jul 1, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P140003-S074
Device name
Impella 2.5 System, Impella CP System and Impella CP System with SmartAssist System, Impella 5.0 System, Impella LD Syst
Applicant
Abiomed, Inc.
Applicant location
Danvers, MA
Received
Jul 1, 2020
Decided
Mar 10, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P140003

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code OZD

FDA's approval statement

As written in FDA's record.

Approval for labeling updates to revise the Instructions for Use and the High-Risk PCI Patient Brochure.

Source documents

Other decisions for Abiomed, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.